Chart of Day: ADC Therapeutics (ADCT) – 3/18

ADC Therapeutics ran higher with its exposure to antibody-drug conjugates (ADCs).

ADC Therapeutics (ADCT) Chart of the Day March 18 2024

Even more exciting, industry leaders love ADC related stocks.

AbbVie recently said it would acquire Immunogen in a $10.1 billion deal. Merck even said it would acquire Daiichi to co-develop and commercialize ADCs, as well. Better, according to Pfizer’s CEO Albert Bourla, ADCs have become one of the hottest opportunities in oncology, which would explain why it recently acquired Seagen for $34 billion. Even better, Pfizer wants to acquire even more ADC companies.

All because ADCs can “deliver a cancer-killing therapy to specifically target and kill cancer cells and minimize damage to healthy ones. Meanwhile, standard chemotherapy is less selective – it can affect both cancer cells and healthy cells,” says CNBC.

With ADCT, the company announced the results of a very successful trial of a combination of ZYNLONTA and Rituximab — a monoclonal antibody medication used to treat certain autoimmune diseases and some cancers — to address relapsed follicular lymphoma (the second most common subtype of non-Hodgkin lymphoma).

“In this first-ever study evaluating the combination of ZYNLONTA and rituximab in patients with relapsed or refractory follicular lymphoma, the overall response rate was 96% and complete response rate was 85%, with a significant number of patients achieving an early response,” said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics.

While there’s potential for higher highs with ADCT and other ADC-related names, wait for the pullback to exhaust itself if you’re thinking of jumping in.

deal of the month

best growth stocks


Bundle package – lifetime subscriptions for all products


Recent posts


Connect with Us

Get FREE Daily Stock Tips

Join and receive market insider stock picks, trade alerts and unique investing insights
This field is for validation purposes and should be left unchanged.
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.

Join Waitlist

We’re sorry, but due to the popularity of our services, we have reached our max number of subscribers and are not currently accepting more. If spots become available, we will be sure to contact you. Please join the waitlist below.
Thank You!

"*" indicates required fields

This field is for validation purposes and should be left unchanged.